Suppr超能文献

人类肾小管对1型多巴胺受体刺激的不同反应取决于血压状态。

Differential human renal tubular responses to dopamine type 1 receptor stimulation are determined by blood pressure status.

作者信息

O'Connell D P, Ragsdale N V, Boyd D G, Felder R A, Carey R M

机构信息

Department of Pharmacology and Therapeutics, University College Cork, Ireland.

出版信息

Hypertension. 1997 Jan;29(1 Pt 1):115-22. doi: 10.1161/01.hyp.29.1.115.

Abstract

We performed the present studies to determine whether a proximal renal tubular dopamine D1-like receptor defect exists in human essential hypertension. Twenty-four subjects were studied (13 normotensive and 11 hypertensive) in a randomized, double-blind, vehicle-controlled study using fenoldopam, a selective D1-like receptor agonist. Subjects were studied in sodium metabolic balance at 300 mEq/d, after which the salt sensitivity of their blood pressure was determined. Fenoldopam at peak doses of 0.1 to 0.2 microgram/kg per minute decreased mean arterial pressure in hypertensive subjects but did not change mean pressure in normotensive subjects. Fenoldopam increased renal plasma flow to a greater extent in hypertensive than normotensive subjects. Fenoldopam increased both urinary and fractional sodium excretions in the hypertensive and normotensive groups. In normotensive but not hypertensive subjects, fenoldopam increased the fractional excretion of lithium and distal sodium delivery. In contrast, both distal fractional sodium reabsorption and sodium-potassium exchange fell significantly in hypertensive subjects. We conclude that human essential hypertension is associated with a reduction in the proximal tubular response to D1-like receptor stimulation compared with normotensive subjects. Hypertensive subjects appear to have a compensatory upregulation of renal vascular and distal tubular D1-like receptor function that offsets the proximal tubular defect, resulting in an enhanced natriuretic response to D1-like receptor stimulation.

摘要

我们开展了本研究,以确定人类原发性高血压患者是否存在近端肾小管多巴胺 D1 样受体缺陷。在一项使用选择性 D1 样受体激动剂非诺多泮的随机、双盲、安慰剂对照研究中,对 24 名受试者(13 名血压正常者和 11 名高血压患者)进行了研究。受试者在每日 300 毫当量的钠代谢平衡状态下接受研究,之后测定其血压的盐敏感性。非诺多泮以每分钟 0.1 至 0.2 微克/千克的峰值剂量给药时,可降低高血压受试者的平均动脉压,但对血压正常受试者的平均血压无影响。与血压正常受试者相比,非诺多泮使高血压受试者的肾血浆流量增加幅度更大。非诺多泮使高血压组和血压正常组的尿钠排泄量和尿钠排泄分数均增加。在血压正常而非高血压受试者中,非诺多泮增加了锂的排泄分数和远端钠输送。相反,高血压受试者的远端钠重吸收分数和钠钾交换均显著下降。我们得出结论,与血压正常受试者相比,人类原发性高血压与近端肾小管对 D1 样受体刺激的反应降低有关。高血压受试者似乎对肾血管和远端肾小管 D1 样受体功能进行了代偿性上调,从而抵消了近端肾小管缺陷,导致对 D1 样受体刺激的利钠反应增强。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验